Of interest, 3 of these patients (head and neck, n = 2; NSCLC, n = 1) were also known to have EGFR mutations and progressed on an EGFR monoclonal antibody or tyrosine kinase inhibitor, suggesting that a PIK3CA mutation could have been a driver of therapeutic resistance. Here, PIK3CA is linked to non-small cell lung carcinoma.